

27. Constantinescu CC, Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. *Phys Med Biol*. 2009;54:2885–2899.
28. Kemp BJ, Hruska CB, McFarland AR, Lenox MW, Lowe VJ. NEMA NU 2-2007 performance measurements of the Siemens Inveon preclinical small animal PET system. *Phys Med Biol*. 2009;54:2359–2376.
29. de Pinieux G, Legrier ME, Poirson-Bichat F, et al. Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. *Am J Pathol*. 2001;159:753–764.
30. Dimitrakopoulou-Strauss A, Strauss LG. The role of ¹⁸F-FLT in cancer imaging: does it really reflect proliferation? *Eur J Nucl Med Mol Imaging*. 2008;35:523–526.
31. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. *Radiology*. 1996;199:751–756.
32. Jadvar H, Xiankui L, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. *Mol Imaging*. 2005;4:91–97.
33. Krause BJ, Souvatzoglou M, Herrmann K, et al. [¹¹C]choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. *Eur J Nucl Med Mol Imaging*. 2010;37:1861–1868.
34. Fei B, Wang H, Wu C, Chiu SM. Choline PET for monitoring early tumor response to photodynamic therapy. *J Nucl Med*. 2010;51:130–138.
35. Mertens K, Slaets D, Lambert B, et al. PET with ¹⁸F-labelled choline-based tracers for tumour imaging: a review of the literature. *Eur J Nucl Med Mol Imaging*. 2010;37:2188–2193.
36. Rosen MA, Jones RM, Yano Y, Budinger TF. Carbon-11 choline: synthesis, purification, and brain uptake inhibition by 2-dimethylaminoethanol. *J Nucl Med*. 1985;26:1424–1428.
37. Kwee S, Turner H, Lim J, Wakano C, Coel M. Dimethylaminoethanol reduces ¹⁸F-fluoroethylcholine uptake in prostate cancer cells [abstract]. *J Nucl Med*. 2006;47(suppl 1):425P.
38. Hara T. ¹⁸F-fluorocholesterol: a new oncologic PET tracer. *J Nucl Med*. 2001;42:1815–1817.
39. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. *Semin Nucl Med*. 2007;37:420–428.
40. Bansal A, Shuyan W, Hara T, Harris RA, DeGrado TR. Biodisposition and metabolism of [¹⁸F]fluorocholesterol in 9L glioma cells and 9L glioma-bearing Fisher rats. *Eur J Nucl Med Mol Imaging*. 2008;35:1192–1203.
41. Leyton J, Smith G, Zhao Y, et al. [¹⁸F]fluoromethyl-[1,2-²H₄]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. *Cancer Res*. 2009;69:7721–7728.

Errata

The article with a DOI of 10.2967/jnumed.111.091231 has been retracted at the request of the Editor in Chief.

In the article “Prognostic Value of ¹⁸F-FDG PET in Monosegmental Stenosis and Myelopathy of the Cervical Spinal Cord” by Floeth et al. (*J Nucl Med*. 2011;52:1385–1391), one author was inadvertently omitted from the byline. The corrected byline and affiliations appear below. The authors regret the error.

Frank W. Floeth^{1,2}, Gabriele Stoffels³, Jörg Herdmann^{1,2}, Sven Eicker¹, Norbert Galldiks^{3,4}, Sascha Rhee², Hans-Jakob Steiger¹, and Karl-Josef Langen³

¹Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany; ²Department of Spine and Pain, St.-Vinzenz-Hospital, Düsseldorf, Germany; ³Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany; and ⁴Department of Neurology, University Hospital Cologne, Cologne, Germany